Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for James C Blair. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at James C Blair har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af James C Blair. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ADYX / Adynxx, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ADYX / Adynxx, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ALDX / Aldeyra Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ALDX / Aldeyra Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ATRA / Atara Biotherapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATRA / Atara Biotherapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ATYR / aTyr Pharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATYR / aTyr Pharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BNGO / Bionano Genomics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-08-23 | BNGO | Domain Partners VIII, L.P. | 15.000 | 6,1250 | 429 | 214,3750 | 91.875 | 35 | 82.5 | -56.565 | -61,57 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BNGO / Bionano Genomics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ESPR / Esperion Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-10-21 | ESPR | DOMAIN PARTERS VII L P | 500.000 | 20,0000 | 500.000 | 20,0000 | 10.000.000 | 210 | 115.3000 | 47.650.000 | 476,50 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ESPR / Esperion Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EVOK / Evoke Pharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EVOK / Evoke Pharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GKOS / Glaukos Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GKOS / Glaukos Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VCYT / Veracyte, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADYX / Adynxx, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VCYT / Veracyte, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADYX / Adynxx, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af James C Blair som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-06-11 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 42.223 | 42.223 | |||||
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 40.138 | 40.138 | |||||
2019-08-20 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
P - Purchase | 20.000 | 20.000 | 5,97 | 119.400 | 119.400 | ||
2019-08-20 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
P - Purchase | 20.000 | 33.439 | 148,82 | 5,70 | 114.000 | 190.602 | |
2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Warrants to Purchase Common Stock |
P - Purchase | 187.500 | 187.500 | 4,00 | 750.000 | 750.000 | ||
2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 250.000 | 813.433 | 44,37 | 4,00 | 1.000.000 | 3.253.732 | |
2019-06-10 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 28.882 | 28.882 | |||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45.054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6.072.088 | ||||||||
2019-05-10 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 522 | 13.439 | 4,04 | ||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 701 | 10.105 | 7,45 | ||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -17.056 | 0 | -100,00 | 27,79 | -473.986 | ||
2019-02-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2019-02-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1.000.000 | 0 | -100,00 | ||||
2018-10-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 14.770 | 14.770 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Warrants to Purchase Common Stock |
P - Purchase | 15.000 | 15.000 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -6.810.098 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -3.682.919 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -6.396.105 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -5.426.808 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -2.986.762 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
P - Purchase | 15.000 | 943.878 | 1,61 | 6,12 | 91.875 | 5.781.253 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 337.694 | 929.878 | 57,03 | 4,59 | 1.550.015 | 4.268.140 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 591.184 | 591.184 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -50.532 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -27.328 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -47.460 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -40.268 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -22.161 | 0 | -100,00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 2.505 | 6.891 | 57,11 | 4,59 | 11.498 | 31.630 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 4.386 | 4.386 | |||||
2018-08-27 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 1.648.359 | 5.634.329 | 41,35 | 1,82 | 3.000.013 | 10.254.479 | |
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-05-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 5.897 | 12.917 | 84,00 | ||||
2018-05-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -32.760 | 0 | -100,00 | ||||
2018-05-17 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -368 | 0 | -100,00 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 282 | 25.730 | 1,11 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 12.444 | 25.448 | 95,69 | 3,19 | 39.696 | 81.179 | |
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -49.632 | 0 | -100,00 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 37.890 | 3.469.029 | 1,10 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.678.432 | 3.431.139 | 95,76 | 3,19 | 5.354.198 | 10.945.333 | |
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -988.285 | 0 | -100,00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -47.963 | 0 | -100,00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -15.731 | 0 | -100,00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20.150 | 0 | -100,00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20.150 | 0 | -100,00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -1.857.036 | 0 | -100,00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -7.333 | 0 | -100,00 | ||||
2017-08-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 6.477 | 9.404 | 221,28 | ||||
2017-08-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 4.835 | 7.020 | 221,28 | ||||
2017-08-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -92.518 | 0 | -100,00 | ||||
2017-08-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -18.450 | 17.056 | -51,96 | 78,61 | -1.450.354 | 1.340.772 | |
2017-06-27 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2.869 | 92.518 | 3,20 | ||||
2017-06-27 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -286.857 | 1.000.000 | -22,29 | ||||
2017-06-12 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 10.000 | 10.000 | |||||
2017-05-23 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2.927 | 2.927 | |||||
2017-05-23 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2.185 | 2.185 | |||||
2017-05-23 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -41.813 | 0 | -100,00 | ||||
2017-05-11 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 49.632 | 49.632 | 100,00 | 4.963.200 | 4.963.200 | ||
2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 368 | 368 | 100,00 | 36.800 | 36.800 | ||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 17.695 | 0 | -100,00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1.071 | 0 | -100,00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1.996 | 0 | -100,00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -38.094 | 0 | -100,00 | 28,35 | -1.079.965 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -3.553.322 | 0 | -100,00 | 28,35 | -100.736.679 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -47.613 | 0 | -100,00 | 28,35 | -1.349.829 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -1.657 | 0 | -100,00 | 28,35 | -46.976 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -285.679 | 0 | -100,00 | 28,35 | -8.099.000 | ||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -14.271 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -20.583 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -11.083 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 49.570 | 49.570 | |||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series E Preferred Stock |
C - Conversion | -482.326 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -597.207 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -836.722 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -1.206.836 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -649.835 | 0 | -100,00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 3.985.970 | 3.985.970 | |||||
2016-09-13 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
J - Other | -1.943.109 | 0 | -100,00 | ||||
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -129 | 3.039 | -4,07 | 8,15 | -1.051 | 24.768 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -32 | 3.168 | -1,00 | 8,71 | -279 | 27.593 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -84 | 3.200 | -2,56 | 8,82 | -741 | 28.224 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -81.094 | 1.943.109 | -4,01 | 8,15 | -660.916 | 15.836.338 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19.718 | 2.024.203 | -0,96 | 8,71 | -171.744 | 17.630.808 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -52.216 | 2.043.921 | -2,49 | 8,82 | -460.545 | 18.027.383 | |
2016-06-13 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 10.000 | 10.000 | |||||
2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -5.880 | 10.328 | -36,28 | 4,70 | -27.636 | 48.542 | |
2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -344.120 | 606.283 | -36,21 | 4,70 | -1.617.364 | 2.849.530 | |
2016-05-26 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 18.000 | 18.000 | |||||
2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -149.765 | 2.096.137 | -6,67 | 6,96 | -1.042.364 | 14.589.114 | |
2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -235 | 3.284 | -6,68 | 6,96 | -1.636 | 22.857 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -61 | 16.208 | -0,37 | 5,02 | -306 | 81.364 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -21 | 16.269 | -0,13 | 5,20 | -109 | 84.599 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -3.603 | 950.403 | -0,38 | 5,02 | -18.087 | 4.771.023 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -1.492 | 954.006 | -0,16 | 5,20 | -7.758 | 4.960.831 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -76 | 16.290 | -0,46 | 5,29 | -402 | 86.174 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -632 | 16.366 | -3,72 | 5,36 | -3.388 | 87.722 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4.424 | 955.498 | -0,46 | 5,29 | -23.403 | 5.054.584 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -37.054 | 959.922 | -3,72 | 5,36 | -198.609 | 5.145.182 | |
2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -75 | 16.998 | -0,44 | 5,22 | -392 | 88.730 | |
2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4.348 | 996.976 | -0,43 | 5,22 | -22.697 | 5.204.215 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -251 | 17.073 | -1,45 | 5,35 | -1.343 | 91.341 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -475 | 17.324 | -2,67 | 5,26 | -2.498 | 91.124 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -148 | 17.799 | -0,82 | 5,22 | -773 | 92.911 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -14.554 | 1.001.324 | -1,43 | 5,35 | -77.864 | 5.357.083 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -27.781 | 1.015.878 | -2,66 | 5,26 | -146.128 | 5.343.518 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -8.669 | 1.043.659 | -0,82 | 5,22 | -45.252 | 5.447.900 | |
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -360.640 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -400.422 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 761.062 | 761.062 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -2.674 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -2.967 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 5.641 | 5.641 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -13.925 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 13.925 | 13.925 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -444.460 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1.299.394 | 0 | -100,00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.743.854 | 1.743.854 | |||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27.128 | ||||||||
2016-01-29 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 19.428 | 19.428 | |||||
2015-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -794.888 | 1.286.857 | -38,18 | ||||
2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -11.836 | 1.052.328 | -1,11 | 7,02 | -83.089 | 7.387.343 | |
2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -202 | 17.947 | -1,11 | 7,02 | -1.418 | 125.988 | |
2015-07-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2.185 | 2.185 | |||||
2015-07-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -41.813 | 0 | -100,00 | ||||
2015-07-10 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 6.286 | 6.286 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -286.983 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -589.100 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 876.083 | 876.083 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -2.130 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -4.371 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 6.501 | 6.501 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Warrant |
M - Exercise | -20.470 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series D Preferred Stock |
C - Conversion | -105.128 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series C Preferred Stock |
C - Conversion | -440.178 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series B Preferred Stock |
C - Conversion | -925.926 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series A Preferred Stock |
C - Conversion | -585.958 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
F - Taxes | -8.700 | 2.068.960 | -0,42 | 18,00 | -156.600 | 37.241.280 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
M - Exercise | 20.470 | 2.077.660 | 1,00 | 7,65 | 156.596 | 15.894.099 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 2.057.190 | 2.057.190 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series A Preferred Stock |
C - Conversion | -14.041 | 0 | -100,00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 14.041 | 14.041 | |||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126.400 | ||||||||
2015-06-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 10.000 | 10.000 | |||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -887.073 | 0 | -100,00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -1.506.901 | 0 | -100,00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -12.143.933 | 0 | -100,00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1.807.820 | 1.807.820 | |||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -6.581 | 0 | -100,00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -11.182 | 0 | -100,00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -90.110 | 0 | -100,00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 13.414 | 13.414 | |||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.565 | 0 | -100,00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -1.954 | 0 | -100,00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3.519 | 3.519 | |||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -464.756 | 0 | -100,00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -939.289 | 0 | -100,00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -798.188 | 0 | -100,00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2.202.233 | 2.245.902 | 5.043,01 | ||||
2015-05-06 |
|
4 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
J - Other | 36.187 | 38.094 | 1.897,59 | ||||
2015-05-06 |
|
4 | TBRA |
Regado Biosciences Inc
Common Stock |
P - Purchase | 277.777 | 3.553.322 | 8,48 | 10,62 | 2.949.992 | 37.736.280 | |
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6.551.090 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95.226 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18.858 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87.338 | ||||||||
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -32.411 | 1.064.164 | -2,96 | 7,07 | -229.146 | 7.523.639 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -7.920 | 1.096.575 | -0,72 | 7,58 | -60.034 | 8.312.038 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -9.832 | 1.104.495 | -0,88 | 7,78 | -76.493 | 8.592.971 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -554 | 18.149 | -2,96 | 7,07 | -3.917 | 128.313 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -135 | 18.703 | -0,72 | 7,58 | -1.023 | 141.769 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -168 | 18.838 | -0,88 | 7,78 | -1.307 | 146.560 | |
2015-03-24 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -350.000 | 2.216.935 | -13,63 | ||||
2015-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -8.528 | 35.506 | -19,37 | 77,70 | -662.626 | 2.758.816 | |
2015-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -500.000 | 2.081.745 | -19,37 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2.827 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1.570 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102.282 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36.913 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104.247 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12.578 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1.725 | 48.025 | -3,47 | 14,00 | -24.150 | 672.350 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2.827 | 49.750 | 6,02 | 8,54 | 24.143 | 424.865 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46.923 | -2,00 | 14,00 | -13.412 | 656.922 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1.570 | 47.881 | 3,39 | 8,54 | 13.408 | 408.904 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46.311 | 46.311 | |||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165.790 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92.105 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7.252.144 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.164.305 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6.111.968 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737.422 | 0 | -100,00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70.000 | 3.091.643 | 2,32 | 14,00 | 980.000 | 43.283.002 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101.132 | 3.021.643 | -3,24 | 14,00 | -1.415.848 | 42.303.002 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165.790 | 3.122.775 | 5,61 | 8,54 | 1.415.847 | 26.668.498 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56.185 | 2.956.985 | -1,86 | 14,00 | -786.590 | 41.397.790 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92.105 | 3.013.170 | 3,15 | 8,54 | 786.577 | 25.732.472 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2.921.065 | 2.921.065 | |||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165.790 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92.105 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7.252.144 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.164.305 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6.111.968 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737.422 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70.000 | 3.091.642 | 2,32 | 14,00 | 980.000 | 43.282.988 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101.132 | 3.021.642 | -3,24 | 14,00 | -1.415.848 | 42.302.988 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165.790 | 3.122.774 | 5,61 | 8,54 | 1.415.847 | 26.668.490 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56.185 | 2.956.984 | -1,86 | 14,00 | -786.590 | 41.397.776 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92.105 | 3.013.169 | 3,15 | 8,54 | 786.577 | 25.732.463 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2.921.064 | 2.921.064 | |||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2.827 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1.570 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102.282 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36.913 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104.247 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12.578 | 0 | -100,00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1.725 | 48.023 | -3,47 | 14,00 | -24.150 | 672.322 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2.827 | 49.748 | 6,03 | 8,54 | 24.143 | 424.848 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46.921 | -2,00 | 14,00 | -13.412 | 656.894 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1.570 | 47.879 | 3,39 | 8,54 | 13.408 | 408.887 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46.309 | 46.309 | |||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7.868 | ||||||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -6.250 | 0 | -100,00 | ||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -22.306 | 0 | -100,00 | ||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -3.006.132 | 0 | -100,00 | ||||
2014-10-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 500.000 | 2.566.935 | 24,19 | 20,00 | 10.000.000 | 51.338.700 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4.606 | 0 | -100,00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -9.443 | 0 | -100,00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 1.841 | 15.890 | 13,10 | 11,00 | 20.251 | 174.790 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 14.049 | 14.049 | |||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -620.776 | 0 | -100,00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1.272.607 | 0 | -100,00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 248.159 | 2.141.542 | 13,11 | 11,00 | 2.729.749 | 23.556.962 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1.893.383 | 1.893.383 | |||||
2014-09-12 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
J - Other | -300.000 | 2.763.294 | -9,79 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -502 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -1.386 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -6.866 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -3.238 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -277 | 11.715 | -2,31 | 16,00 | -4.432 | 187.440 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 502 | 11.992 | 4,37 | 8,79 | 4.413 | 105.410 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 11.490 | 11.490 | |||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -67.755 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -186.828 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -925.479 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -436.485 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -37.224 | 1.579.323 | -2,30 | 16,00 | -595.584 | 25.269.168 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 67.755 | 1.616.547 | 4,37 | 8,79 | 595.566 | 14.209.448 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 1.548.792 | 1.548.792 | |||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1.165 | 0 | -100,00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -7.043 | 0 | -100,00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -8.792 | 0 | -100,00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 17.000 | 17.000 | |||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -579.630 | 0 | -100,00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -657.192 | 0 | -100,00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -820.320 | 0 | -100,00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 419.744 | 2.476.886 | 20,40 | 8,00 | 3.357.952 | 19.815.088 | |
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2.057.142 | 2.057.142 | |||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85.100 | ||||||||
2014-06-19 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 12.414 | 12.414 | |||||
2014-05-22 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 50.000 | 50.000 | |||||
2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 21.250 | 1.973.389 | 1,09 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.882 | 0 | -100,00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 9.208 | 9.208 | |||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60.576 | 0 | -100,00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60.576 | 0 | -100,00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -755.263 | 0 | -100,00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -486.316 | 0 | -100,00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39.063 | 1.952.139 | -1,96 | 8,00 | -312.504 | 15.617.112 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39.063 | 1.952.139 | -1,96 | 8,00 | -312.504 | 15.617.112 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60.576 | 1.991.202 | 3,14 | 5,16 | 312.572 | 10.274.602 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60.576 | 1.991.202 | 3,14 | 5,16 | 312.572 | 10.274.602 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1.909.113 | 1.909.113 | |||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20.716 | ||||||||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | 6,79 | -169.750 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -17.500 | 0 | -100,00 | 11,02 | -192.850 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12.500 | 0 | -100,00 | 4,75 | -59.375 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12.500 | 0 | -100,00 | 6,84 | -85.500 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12.500 | 0 | -100,00 | 4,63 | -57.875 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12.500 | 0 | -100,00 | 7,65 | -95.625 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12.500 | 0 | -100,00 | 1,70 | -21.250 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -27.500 | 0 | -100,00 | 14,00 | -385.000 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -78.369 | 0 | -100,00 | 14,00 | -1.097.166 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -7.313.241 | 0 | -100,00 | 14,00 | -102.385.374 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -50.743 | 0 | -100,00 | 14,00 | -710.402 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2.972.678 | 0 | -100,00 | 14,00 | -41.617.492 | ||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -7.430 | 0 | -100,00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -15.799 | 0 | -100,00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -10.661 | 0 | -100,00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -435.663 | 0 | -100,00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -926.321 | 0 | -100,00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -625.065 | 0 | -100,00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 33.890 | 33.890 | |||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 1.987.049 | 1.987.049 | |||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -1.367.020 | 0 | -100,00 | ||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -765.532 | 2.972.678 | -20,48 | 14,00 | -10.717.448 | 41.617.492 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1.367.020 | 3.738.210 | 57,65 | 7,84 | 10.717.437 | 29.307.566 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -23.317 | 0 | -100,00 | ||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -13.058 | 50.743 | -20,47 | 14,00 | -182.812 | 710.402 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23.317 | 63.801 | 57,60 | 7,84 | 182.805 | 500.200 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 156 | 156 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -156 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -9.469 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3.535 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 21.041 | 21.041 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -21.041 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -1.276.243 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -476.464 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 13.004 | 13.004 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.752.707 | 1.752.707 | |||||
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -2.230 | 34.907 | -6,00 | 6,56 | -14.629 | 228.990 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -1.010 | 37.137 | -2,65 | 6,01 | -6.070 | 223.193 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -204.315 | 3.590.931 | -5,38 | 6,56 | -1.340.306 | 23.556.507 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -92.445 | 3.795.246 | -2,38 | 6,01 | -555.594 | 22.809.428 |
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 6.008 | 6.008 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -10.068 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -38.941 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -9.378 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -6.071 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 352.351 | 352.351 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -590.403 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -2.283.114 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -549.833 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -356.111 | 0 | -100,00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 54.390 | 54.390 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 3.189.058 | 3.189.058 | |||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -5.053 | 0 | -100,00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -680.972 | 0 | -100,00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -17.677 | 0 | -100,00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -2.382.322 | 0 | -100,00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 22.730 | 22.730 | |||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 3.063.294 | 3.063.294 | |||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -19.006 | 0 | -100,00 | ||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -1.114.327 | 0 | -100,00 | ||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 19.006 | 19.006 | |||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 1.114.327 | 1.114.327 | |||||
2013-09-24 | 3 | EVOK |
Evoke Pharma Inc
Common Stock |
5.250 | ||||||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -7.407 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -2.899 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -4.233 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series E Preferred Stock |
C - Conversion | -225.913 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -894.120 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -270.568 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -394.969 | 0 | -100,00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 7.407 | 14.920 | 98,59 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 2.899 | 7.513 | 62,83 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 4.233 | 4.614 | 1.111,02 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
P - Purchase | 750.000 | 2.571.117 | 41,18 | 4,00 | 3.000.000 | 10.284.468 | |
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 225.913 | 1.821.117 | 14,16 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 894.120 | 1.595.204 | 127,53 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 270.568 | 701.084 | 62,85 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 394.969 | 430.516 | 1.111,12 | ||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
35.547 | ||||||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
381 | ||||||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
17.171 | ||||||||
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331.873 | 1.857.036 | 21,76 | 6,03 | 1.999.999 | 11.191.242 | |
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7.333 | 7.333 | 6,03 | 44.192 | 44.192 | ||
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988.285 | 988.285 | 6,03 | 5.955.801 | 5.955.801 | ||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47.963 | ||||||||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1.525.163 | ||||||||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15.731 | ||||||||
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331.873 | 1.897.336 | 21,20 | 6,03 | 1.999.999 | 11.434.106 | |
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7.333 | 7.333 | 6,03 | 44.192 | 44.192 | ||
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988.285 | 988.285 | 6,03 | 5.955.801 | 5.955.801 | ||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47.963 | ||||||||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1.565.463 | ||||||||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15.731 | ||||||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 1.193 | 1.193 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -8.346 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -30.462 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 70.042 | 70.042 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -489.320 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1.786.012 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4.791 | 35.253 | 15,73 | 14,00 | 67.074 | 493.542 | |
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 30.462 | 30.462 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 280.923 | 2.066.935 | 15,73 | 14,00 | 3.932.922 | 28.937.090 | |
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1.786.012 | 1.786.012 | |||||
2013-06-25 | 3 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
21.471 | ||||||||
2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -114 | 38.147 | -0,30 | 5,01 | -571 | 191.116 |
2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -10.516 | 3.887.691 | -0,27 | 5,01 | -52.685 | 19.477.332 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -22.423 | 3.898.207 | -0,57 | 5,37 | -120.412 | 20.933.372 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -32.855 | 3.920.630 | -0,83 | 5,40 | -177.417 | 21.171.402 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -244 | 38.261 | -0,63 | 5,37 | -1.310 | 205.462 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -359 | 38.505 | -0,92 | 5,40 | -1.939 | 207.927 |
2013-06-19 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 45.000 | 45.000 | |||||
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -959 | 38.864 | -2,41 | 5,40 | -5.179 | 209.866 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -425 | 39.823 | -1,06 | 5,03 | -2.138 | 200.310 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -87.812 | 3.953.485 | -2,17 | 5,40 | -474.185 | 21.348.819 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -38.897 | 4.041.297 | -0,95 | 5,03 | -195.652 | 20.327.724 |
2013-06-14 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 12.414 | 12.414 | |||||
2013-06-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to buy) |
A - Award | 25.000 | 25.000 | |||||
2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -59 | 40.248 | -0,15 | 5,00 | -295 | 201.240 |
2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -5.337 | 4.080.194 | -0,13 | 5,00 | -26.685 | 20.400.970 |
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -159.192 | 2.581.745 | -5,81 | 64,58 | -10.280.619 | 166.729.092 | |
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2.779 | 44.034 | -5,94 | 64,58 | -179.468 | 2.843.716 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -232 | 40.307 | -0,57 | 4,50 | -1.044 | 181.382 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -251 | 40.539 | -0,62 | 4,70 | -1.180 | 190.533 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -21.276 | 4.085.531 | -0,52 | 4,50 | -95.742 | 18.384.890 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -22.966 | 4.106.807 | -0,56 | 4,70 | -107.940 | 19.301.993 | |
2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23.210 | 2.371.190 | -0,97 | 6,62 | -153.650 | 15.697.278 |
2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -71.578 | 7.313.241 | -0,97 | 6,62 | -473.846 | 48.413.655 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.567 | 2.394.400 | -0,07 | 6,72 | -10.530 | 16.090.368 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11.386 | 2.395.967 | -0,47 | 6,71 | -76.400 | 16.076.939 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.217 | 2.407.353 | -0,50 | 6,52 | -79.655 | 15.695.942 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.832 | 7.384.819 | -0,07 | 6,72 | -32.471 | 49.625.984 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -35.114 | 7.389.651 | -0,47 | 6,71 | -235.615 | 49.584.558 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -37.676 | 7.424.765 | -0,50 | 6,52 | -245.648 | 48.409.468 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.374 | 2.419.570 | -0,18 | 5,35 | -23.401 | 12.944.700 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -893 | 40.484 | -2,16 | 5,49 | -4.903 | 222.257 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13.490 | 7.462.441 | -0,18 | 5,35 | -72.172 | 39.924.059 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.743 | 78.369 | -2,18 | 5,49 | -9.569 | 430.246 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.510 | 2.423.944 | -0,23 | 5,22 | -28.762 | 12.652.988 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7.925 | 2.429.454 | -0,33 | 5,19 | -41.131 | 12.608.866 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -92 | 41.377 | -0,22 | 5,22 | -480 | 215.988 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 41.469 | -0,32 | 5,19 | -695 | 215.224 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -182 | 80.112 | -0,23 | 5,22 | -950 | 418.185 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -261 | 80.294 | -0,32 | 5,19 | -1.355 | 416.726 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16.995 | 7.475.931 | -0,23 | 5,22 | -88.714 | 39.024.360 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24.442 | 7.492.926 | -0,33 | 5,19 | -126.854 | 38.888.286 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -8.020 | 2.437.379 | -0,33 | 5,16 | -41.383 | 12.576.876 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.636 | 2.445.399 | -0,39 | 5,28 | -50.878 | 12.911.707 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -135 | 41.603 | -0,32 | 5,16 | -697 | 214.671 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -163 | 41.738 | -0,39 | 5,28 | -861 | 220.377 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -265 | 80.555 | -0,33 | 5,16 | -1.367 | 415.664 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -318 | 80.820 | -0,39 | 5,28 | -1.679 | 426.730 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24.736 | 7.517.368 | -0,33 | 5,16 | -127.638 | 38.789.619 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -29.719 | 7.542.104 | -0,39 | 5,28 | -156.916 | 39.822.309 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.020 | 2.455.035 | -0,20 | 5,36 | -26.907 | 13.158.988 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7.733 | 2.460.055 | -0,31 | 5,40 | -41.758 | 13.284.297 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -85 | 41.901 | -0,20 | 5,36 | -456 | 224.589 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -131 | 41.986 | -0,31 | 5,40 | -707 | 226.724 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -166 | 81.138 | -0,20 | 5,36 | -890 | 434.900 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -256 | 81.304 | -0,31 | 5,40 | -1.382 | 439.042 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.480 | 7.571.823 | -0,20 | 5,36 | -82.973 | 40.584.971 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23.848 | 7.587.303 | -0,31 | 5,40 | -128.779 | 40.971.436 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6.346 | 2.467.788 | -0,26 | 5,38 | -34.141 | 13.276.699 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.118 | 2.474.134 | -0,17 | 5,34 | -21.990 | 13.211.876 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -107 | 42.117 | -0,25 | 5,38 | -576 | 226.589 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -70 | 42.224 | -0,17 | 5,34 | -374 | 225.476 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -210 | 81.560 | -0,26 | 5,38 | -1.130 | 438.793 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -136 | 81.770 | -0,17 | 5,34 | -726 | 436.652 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19.569 | 7.611.151 | -0,26 | 5,38 | -105.281 | 40.947.992 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.700 | 7.630.720 | -0,17 | 5,34 | -67.818 | 40.748.045 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.154 | 2.478.252 | -0,21 | 5,32 | -27.419 | 13.184.301 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.701 | 2.483.406 | -0,51 | 5,22 | -66.299 | 12.963.379 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42.294 | -0,21 | 5,32 | -468 | 225.004 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -215 | 42.382 | -0,50 | 5,22 | -1.122 | 221.234 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 81.906 | -0,21 | 5,32 | -910 | 435.740 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -420 | 82.077 | -0,51 | 5,22 | -2.192 | 428.442 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.892 | 7.643.420 | -0,21 | 5,32 | -84.545 | 40.662.994 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -39.168 | 7.659.312 | -0,51 | 5,22 | -204.457 | 39.981.609 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -3.839 | 2.496.107 | -0,15 | 5,06 | -19.425 | 12.630.301 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4.039 | 2.499.946 | -0,16 | 5,01 | -20.235 | 12.524.729 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -65 | 42.597 | -0,15 | 5,06 | -329 | 215.541 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -69 | 42.662 | -0,16 | 5,01 | -346 | 213.737 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11.841 | 7.698.480 | -0,15 | 5,06 | -59.915 | 38.954.309 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.454 | 7.710.321 | -0,16 | 5,01 | -62.395 | 38.628.708 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -127 | 82.497 | -0,15 | 5,06 | -643 | 417.435 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 82.624 | -0,16 | 5,01 | -671 | 413.946 |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -1.651 | 46.813 | -3,41 | 24,51 | -40.466 | 1.147.387 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2.132 | 48.464 | -4,21 | 24,69 | -52.639 | 1.196.576 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -417 | 50.596 | -0,82 | 24,44 | -10.191 | 1.236.566 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -98.349 | 2.740.937 | -3,46 | 24,51 | -2.410.534 | 67.180.366 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -126.868 | 2.839.286 | -4,28 | 24,69 | -3.132.371 | 70.101.971 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -24.783 | 2.966.154 | -0,83 | 24,44 | -605.697 | 72.492.804 | |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.145 | 2.503.985 | -0,21 | 5,01 | -25.776 | 12.544.965 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7.635 | 2.509.130 | -0,30 | 5,01 | -38.251 | 12.570.741 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42.731 | -0,21 | 5,01 | -441 | 214.082 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -130 | 42.819 | -0,30 | 5,01 | -651 | 214.523 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -170 | 82.758 | -0,20 | 5,01 | -852 | 414.618 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -253 | 82.928 | -0,30 | 5,01 | -1.268 | 415.469 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.865 | 7.722.775 | -0,21 | 5,01 | -79.484 | 38.691.103 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23.548 | 7.738.640 | -0,30 | 5,01 | -117.975 | 38.770.586 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.998 | 2.516.765 | -0,08 | 5,01 | -10.010 | 12.608.993 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34 | 42.949 | -0,08 | 5,01 | -170 | 215.174 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6.160 | 7.762.188 | -0,08 | 5,01 | -30.862 | 38.888.562 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -66 | 83.181 | -0,08 | 5,01 | -331 | 416.737 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10.076 | 2.518.763 | -0,40 | 5,02 | -50.582 | 12.644.190 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2.967 | 2.528.839 | -0,12 | 5,00 | -14.835 | 12.644.195 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 42.983 | -0,40 | 5,02 | -858 | 215.775 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43.154 | -0,12 | 5,00 | -255 | 215.770 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -334 | 83.247 | -0,40 | 5,02 | -1.677 | 417.900 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -99 | 83.581 | -0,12 | 5,00 | -495 | 417.905 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -31.075 | 7.768.348 | -0,40 | 5,02 | -155.996 | 38.997.107 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.148 | 7.799.423 | -0,12 | 5,00 | -45.740 | 38.997.115 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2.951 | 2.531.806 | -0,12 | 5,01 | -14.785 | 12.684.348 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.763 | 2.534.757 | -0,23 | 5,00 | -28.815 | 12.673.785 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43.205 | -0,12 | 5,01 | -256 | 216.457 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 43.256 | -0,23 | 5,00 | -490 | 216.280 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 83.680 | -0,12 | 5,01 | -491 | 419.237 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -191 | 83.778 | -0,23 | 5,00 | -955 | 418.890 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.100 | 7.808.571 | -0,12 | 5,01 | -45.591 | 39.120.941 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -17.770 | 7.817.671 | -0,23 | 5,00 | -88.850 | 39.088.355 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9.769 | 2.540.520 | -0,38 | 4,85 | -47.380 | 12.321.522 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -164 | 43.354 | -0,38 | 4,85 | -795 | 210.267 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -30.134 | 7.835.441 | -0,38 | 4,85 | -146.150 | 38.001.889 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -322 | 83.969 | -0,38 | 4,85 | -1.562 | 407.250 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -18.537 | 2.550.289 | -0,72 | 4,71 | -87.309 | 12.011.861 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11.105 | 2.568.826 | -0,43 | 5,00 | -55.525 | 12.844.130 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -314 | 43.518 | -0,72 | 4,71 | -1.479 | 204.970 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -188 | 43.832 | -0,43 | 5,00 | -940 | 219.160 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -57.165 | 7.865.575 | -0,72 | 4,71 | -269.247 | 37.046.858 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34.248 | 7.922.740 | -0,43 | 5,00 | -171.240 | 39.613.700 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -613 | 84.291 | -0,72 | 4,71 | -2.887 | 397.011 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -367 | 84.904 | -0,43 | 5,00 | -1.835 | 424.520 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15.320 | 2.579.931 | -0,59 | 5,27 | -80.736 | 13.596.236 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16.660 | 2.595.251 | -0,64 | 5,40 | -89.964 | 14.014.355 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -260 | 44.020 | -0,59 | 5,27 | -1.370 | 231.985 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -282 | 44.280 | -0,63 | 5,40 | -1.523 | 239.112 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -47.247 | 7.956.988 | -0,59 | 5,27 | -248.992 | 41.933.327 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51.377 | 8.004.235 | -0,64 | 5,40 | -277.436 | 43.222.869 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -507 | 85.271 | -0,59 | 5,27 | -2.672 | 449.378 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -551 | 85.778 | -0,64 | 5,40 | -2.975 | 463.201 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13.790 | 2.611.911 | -0,53 | 5,38 | -74.190 | 14.052.081 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -36.324 | 2.625.701 | -1,36 | 5,45 | -197.966 | 14.310.070 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -234 | 44.562 | -0,52 | 5,38 | -1.259 | 239.744 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -616 | 44.796 | -1,36 | 5,45 | -3.357 | 244.138 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -456 | 86.329 | -0,53 | 5,38 | -2.453 | 464.450 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1.201 | 86.785 | -1,36 | 5,45 | -6.545 | 472.978 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -42.525 | 8.055.612 | -0,53 | 5,38 | -228.784 | 43.339.193 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -111.022 | 8.098.137 | -1,35 | 5,45 | -605.070 | 44.134.847 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -25.354 | 2.662.025 | -0,94 | 5,11 | -129.559 | 13.602.948 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -14.966 | 2.687.379 | -0,55 | 5,02 | -75.129 | 13.490.643 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -430 | 45.412 | -0,94 | 5,11 | -2.197 | 232.055 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -254 | 45.842 | -0,55 | 5,02 | -1.275 | 230.127 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -839 | 87.986 | -0,94 | 5,11 | -4.287 | 449.608 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -495 | 88.825 | -0,55 | 5,02 | -2.485 | 445.902 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -78.188 | 8.210.159 | -0,94 | 5,11 | -399.541 | 41.953.912 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -46.153 | 8.288.347 | -0,55 | 5,02 | -231.688 | 41.607.502 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19.080 | 2.702.345 | -0,70 | 5,19 | -99.025 | 14.025.171 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12.615 | 2.721.425 | -0,46 | 5,35 | -67.490 | 14.559.624 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -324 | 46.096 | -0,70 | 5,19 | -1.682 | 239.238 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -214 | 46.420 | -0,46 | 5,35 | -1.145 | 248.347 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -58.838 | 8.334.500 | -0,70 | 5,19 | -305.369 | 43.256.055 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -38.903 | 8.393.338 | -0,46 | 5,35 | -208.131 | 44.904.358 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -631 | 89.320 | -0,70 | 5,19 | -3.275 | 463.571 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -418 | 89.951 | -0,46 | 5,35 | -2.236 | 481.238 |
2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 66.462 | 159.896 | 71,13 | ||||
2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1.000.000 | 5.772.968 | -14,76 | ||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
2.222.175 | ||||||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
16.733 | ||||||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
5.868 | ||||||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -16.529 | 0 | -100,00 | ||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2.227.596 | 0 | -100,00 | ||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 5.777 | 22.306 | 34,95 | 9,00 | 51.993 | 200.754 | |
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 16.529 | 16.529 | |||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 778.536 | 3.006.132 | 34,95 | 9,00 | 7.006.824 | 27.055.188 | |
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 2.227.596 | 2.227.596 | |||||
2012-07-18 | 3 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
6.250 | ||||||||
2012-06-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 12.414 | 12.414 | |||||
2012-06-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to buy) |
A - Award | 17.500 | 17.500 | |||||
2012-06-08 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 93.434 | 93.434 | |||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1.200.000 | 6.772.968 | -15,05 | ||||
2012-05-01 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 50.000 | 50.000 | |||||
2012-03-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -39.136 | 85.186 | -31,48 | 5,16 | -201.942 | 439.560 | |
2012-03-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -1.656.581 | 3.606.002 | -31,48 | 5,16 | -8.547.958 | 18.606.970 | |
2007-05-09 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | 3.457 | 3.457 | |||||
2007-05-09 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | -17.740 | 0 | -100,00 | ||||
2005-05-04 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | 5.840 | 5.840 | |||||
2005-05-04 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | -584.000 | 1.168.455 | -33,32 |